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Abstract
Background: In preclinical research MatrixgelTM Basement Membrane Matrix (MG) is used frequently for the
establishment of syngeneic and xenograft cancer models. Limited information on its influence on parameters
including; tumor growth, vascularization, hypoxia and imaging characteristics is currently available. This study
evaluates the potential effect of matrigel use in a human head and neck cancer xenograft model (FaDu;
hypopharyngeal carcinoma) in NMRI nude mice. The FaDu cell line was chosen based on its frequent use in
studies of cancer imaging and tumor microenvironment.
Methods: NMRI nude mice (n = 34) were divided into two groups and subcutaneously injected with FaDu cells
in medium either including (+MG) or excluding matrigel (−MG). In sub study I seven mice from each group
(+MG, n = 7; −MG, n = 7) were 18F- fluorodeoxyglucose (18F-FDG) PET/CT scanned on Day 5, 8, 12, 15, and 19.
In sub study II ten mice from each group (+MG, n = 10; −MG, n = 10) were included and tumors collected for
immunohistochemistry (IHC) analysis of tumor microenvironment including; proliferation ratio, micro vessel
density, average vessel area, hypoxia, nuclear density, and necrosis. Tumors for IHC were collected according
to size (200–400 mm3, 500–700 mm3, 800–1100 mm3).
Results: FDG uptake and tumor growth was statistically compatible for the tumors established with or without
MG. The IHC analysis on all parameters only identified a significantly higher micro vessel density for tumor size
500–700 mm3 and 800–1100 mm3 and average vessel area for tumor size 500–700 mm3 in the −MG group.
Comparable variations were observed for tumors of both the +MG and −MG groups. No difference in tumor
take rate was observed between groups in study.
Conclusions: Matrigel did not affect tumor growth or tumor take for the FaDu xenograft model evaluated.
Tumors in the -MG group displayed increased angiogenesis compared to the +MG tumors. No difference in
18F-FDG PET uptake for tumors of different groups was found. Based on these observations the influence of
matrigel on tumor imaging and tumor microenvironment seems minor for this particular xenograft model.
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Background
Human cancer xenografts in immunodeficient mice are
widely used in cancer research and provide vital models
for the study of tumor growth, tumor development, and
the response to therapy in preclinical research. Several
human cancer cell linescan be succesfully implanted
onto immune deficient mouse models, but variations in
take rate and growth of solid tumors makes their use
challenging. MatrixgelTM Basement Membrane Matrix
(Matrigel or MG) is commonly used to improve tumor
take and growth [1]. Matrigel was originally extracted from
connective tissue and research from the last century has
shown that the extracts form matrix structures, and provide
surrounding cells with substrates for growth promotion
and development [1–3]. The reconstructed basement mem-
brane complex includes; laminin, growth factors, entactin,
and type IV collagen [3–5]. Studies have evaluated the ad-
vantages of MG for various cell lines [6–9] and generally it
has been found to improve tumor take and growth. No
change in tumor development and microenvironment is
stated in these studies and reviews [4, 8, 9]. Isolated constit-
uents from MG have been tested for impact on cell growth.
However, no single substance was identified as the main
mediator of effects [1, 10]. MG hereby lacks a fully defined
impact on tumor growth, which could be a possible source
of error in translation. By legislation the number of animals
in preclinical research must be kept as low as possible while
maintaining adequate power of studies. Enhancement of
tumor growth by including MG can be used to decrease
the number of animals in a study, but could also be a
potential source of error from a translational perspec-
tive. 18F-FDG PET/CT is clinically used for head and
neck cancer in relation to staging, therapy planning
and response to therapy [11]. FaDu head and neck can-
cer xenograft models are widely used for studies of
PET imaging, tumor microenvironment, and radiation
therapy in preclinical research [12–14]. The description
of MG use for tumor inoculation in studies is not always
specified. Accordingly, an understanding of possible im-
pact of MG use is of great importance. The aim of this
study was to investigate the influence of MG use, on
tumor and imaging characteristics of FaDu hypopharyn-
geal carcinoma cells inoculated subcutaneously on NMRI
nude mice.
Methods
Tumor model
All experimental procedures were approved by the Danish
Animal Welfare Council, the Danish Ministry of Justice.
Dulbecco’s Modified Eagle Medium were supplemented
with 10 % Fetal Calf Serum (FCS) and 1 % penicillin-
streptomycin for growth of FaDu cells in culture flaks until
confluency, retained in 5 % CO2 incubator at 37 ° C. Six
weeks old female NMRI nude (Naval Medical Research
Institute) mice were purchased from Taconic Europe
(Borup, Denmark). After one week of adaptation, 34
animals were inoculated with FaDu tumor cells sub-
cutaneously on both left and right flank. Half of the
mice (n = 17) were injected with a suspension for each
tumor consisting of 2.5 × 106 FaDu cells in 50 μL Dul-
becco’s Modified Eagle Medium (Life Technologies,
Carlsbad, CA, USA) (−MG group; n = 17). For +MG
group (n = 17) 50 μL Matrixgel™ Basement Membrane
Matrix (BD Biosciences, San Jose, CA, USA) was added
and a total volume of 100 μL containing 2.5 × 106 FaDu
cells injected. Tumor size and weight were measured con-
tinuously from day 5 post implant to follow the develop-
ment of tumors and monitor the health of the mice. Mice
were housed in IVC rack from Techniplast in Type III
SPF cages with 8 mice in each cage. Purified water and
chow food was available ad libitum for mice unless any-
thing else is described.
Group determination
Of the 34 mice included in study; 14 mice (+MG, n = 7;
−MG, n = 7) were randomized to sub study I where all
mice were 18F- fluorodeoxyglucose (18F-FDG) PET/CT
scanned on Day 5, 8, 12, 15, and 19. In sub study II that
included ten mice from the +MG group (n = 10) and ten
mice from the -MG group (n = 10), tumors were collected
when reaching predetermined sizes (200–400 mm3, 500–
700 mm3, 800–1100 mm3) for immunohistochemistry
(IHC) analysis of tumor characteristics.
Volume determination
Tumor volume determination with external caliper was
made by measuring the greatest longitudinal diameter
and transverse diameter. Tumor volume was then calcu-
lated by following ellipsoid equation [15, 16]:
Tumor Volume ¼ π ⋅ longitudinal diameter þ transverse diameter
2
 3
⋅
1
6
Tumor volumes determined from 18F-FDG PET/CT
were generated by manually drawing regions of interest
(ROIs) to cover the entire tumor by numerous tomo-
graphic voxels, and summation of these defined the 3D
tumor volume.
18F-FDG PET/CT imaging – sub study I
Mice were injected via the tail vein with a mean activity
of 8.90 ± 1.55 MBq (Mean ± SD) 18F-FDG in 0.2 mL
0.9 % isotonic saline solution. Prior to injection all mice
were fasted for approximately 12 h to minimize the vari-
ation in 18F-FDG uptake [17]. For injection, distribution,
and scanning, all mice were kept anaesthetized with 3 %
sevoflurane (Abbott Scandinavia AB, Solna, Sweden) mixed
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with 35 % O2 and 65 % N2. Body temperature was kept
stable by external heating device when anaesthetized, and
positioned on a heating pad during scan. 18F-FDG PET/CT
imaging was performed on Siemens Inveon® Small Animal
Scanner (Siemens Medical Systems, PA, USA). The proto-
col included a five minute PET scan followed by a CT scan
with attenuation correction to be used for reconstruction.
Reconstruction of PET scans were performed using
maximum a posteriori (MAP) reconstruction algorithm
(voxel size: 0.815 × 0.815 × 0.796 mm; resolution (FWHM)
1.2 mm). Reconstructed images were analyzed with Inveon
Research Workspace software (Siemens Medical Systems,
PA, USA). Tracer uptake was determined as mean and
maximum % injected dose pr. gram of tumor (%ID/g)
(1 gram per cm3), and mean and maximum standardized
uptake value (SUV), corrected for decay.
Tumor microenvironment – sub study II
Tumors were collected when reaching a size of 200–
400 mm3 (+MG; n = 6, −MG; n = 5), 500–700 mm3 (+MG;
n = 7, −MG; n = 6), and 800–1100 mm3 (+MG; n = 6,
−MG; n = 4). Collection of tumors for IHC staining was
initiated two weeks post injection of FaDu cells and the
collection periods lasted for two weeks. Two hours prior
to euthanasia 0.06 mg/g pimonidazole was injected i.p..
Tumors were fixed in 4 % formaldehyde for 24 h, hereafter
transferred to 70 % ethanol, and finally embedded in par-
affin and cut into 4 μm slices. Each tumor was stained
with the following antibodies; pimonidazole (PIMO;
hypoxia) (HypoxyProbe-Omni Kit, HypoxyProbe Inc.,
Burlington, USA), Ki-67 (proliferation) (Dako; M7240),
and CD31 (endothelial cell marker) (Abcam; ab28364). In
addition haematoxylin eosin (HE) staining was performed.
Antibody concentrations were optimized on tumor sam-
ples from mice included in this study for optimal binding
specificity. The following concentrations were used for
analysis; PIMO 1:400, Ki-67 1:400, and CD31 1:50.
Deparaffination was performed by heating slides for
1 h at 40 ° C, increasing temperature to 60 °C and incubat-
ing for one additional hour. Slides were subsequently
treated with xylene and rehydrated in descending concen-
trations of ethanol (99, 96, 70 %). Slides for Ki-67 antibody
staining were furthermore exposed to microwave heating
after rehydration to retrieve optimal binding. Endogenous
peroxidase was blocked by Peroxidase Blocking Reagent
(Dako, Glostrup, Denmark) for 8 min followed by Bovine
Serum Albumin (BSA) blocking with 2 % BSA for 10 min
to avoid unspecific binding of antibodies. Primary anti-
body incubated for 1 h followed by secondary biotinylated
EnVision FLEX™ (Dako, Glostrup, Denmark) incubation
for 40 min. Finally antibody staining was evoked by
3,3′-Diaminobenzidine (DAB) (Dako, Glostrup, Denmark)
incubation for 10 min and counterstained with haema-
toxylin. Between all steps slides were rinsed in phosphate
buffered saline (PBS, 0.2 M, pH= 7.4). After dehydration
in increasing alcohol concentrations cover slides were
mounted and slides scanned on an Axio scanner (Axio
scan, Carl Zeiss, Germany). The Following parameters
were analyzed; cell density, hypoxia percentages, micro
vessel density (MVD), average vessel area, non-viable cell
percentages, and proliferation percentages. Cell density
and hypoxia was determined using the publicly available
software Fiji (ImageJ). For nuclear density a nuclei count
threshold of 50 pixels2 to infinity was used (pixel size
0.022 × 0.022 μm). The percentage of tumor hypoxia was
evaluated using Color Deconvolution based on pimonida-
zole DAB-H staining. Based on constructed binary images
(threshold between 210 and 220 RGB values of intensity)
the percentage of hypoxia positive stained area in tumor
slides was determined. MVD and average vessel area was
determined using online image segmentation and endo-
thelial cell analysis software CAIMAN (CAncer IMage
ANalysis: http://www.caiman.org.uk) [18] in 5 selected
ROIs. ROIs, excluding necrotic regions and artifacts,
were manually drawn to represent entire slide (pixel
size 0.088 × 0.088 μm). Non-viable cell counts were de-
termined in Fiji using the Advanced Weka Segmenta-
tion plug-in. Regions of viable cells, non-viable cells,
and background in slide were marked to train the clas-
sifier and determine final segmentation. Calculation
was made from the result image constructed by classifier.
Proliferation in tumors was calculated using the online au-
tomated image analysis application ImmunoRatio (http://
jvsmicroscope.uta.fi/sites/default/files/software/immunor-
atio-plugin/index.html) [19]. Five defined ROIs represent-
ing entire slide, excluding necrosis and artifacts, were
manually drawn and uploaded to define percentage of
Fig. 1 Tumor growth curve based on 18F-FDG PET/CT. Tumor volume
obtained by drawing region of interest (ROI) enclosing tumor on PET/
CT images. No significant difference was found between groups at any
time point. All data was obtained from 18F-FDG PET/CT. Days are
counted from the day of inoculation (Day 0)
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Fig. 2 Transverse section of an 18F-FDG PET/CT image of mice with subcutaneous FaDu tumors. 18F-FDG PET/CT scans 1 h after 18F-FDG injection.
Region of interests encapsulate tumor on each side of the flank. a and c +MG mouse at scan day 8 and 19, respectively. b and d −MG mouse
scan day 8 and 19, respectively. Scale bar is indicated in %ID/g for all images calculated from a specific mass of 1 g/cm3. Scan day represents
number of days after inoculation
Fig. 3 Graphic presentation of tumor uptake results obtained from 18F-FDG PET/CT scan data. Uptake obtained from ROIs drawn on tumor areas
calculated as mean (a) and maximum (b) %ID/g from a specific mass of 1 g/cm3 and also as mean (c) and maximum (d) standardized uptake
value (SUV). All data in plots obtained from 18F-FDG PET/CT scans on Siemens Inveon Small Animal scanner 1 h post injection of tracer
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proliferating cells in total nuclei area (pixel size 0.088 ×
0.088 μm).
Statistical analysis
Statistical analysis was performed in GraphPad 6 (Graph-
Pad Software, CA, USA). Comparison between groups of
data from PET/CT scan was performed using Student’s T-
test. Results are presented as Mean ± SEM (Standard Error
of Mean). Analysis of data from histological staining’s was
performed using One-Way ANOVA variance analysis with
Holm-Sidak’s post hoc test for multiple comparisons test
to evaluate differences between groups of different tumor
sizes. A p-value < 0.05 was considered statistically signifi-
cant in all tests.
Results and discussion
Tracer uptake and tumor volume determined by 18F-FDG
PET/CT scan
Data obtained from 18F-FDG PET/CT identified no sig-
nificant difference in FDG tumor uptake or tumor size
between the +MG and -MG groups on each scan day,
shown in Figs. 1 and 3. A tendency for increased growth
rate of the tumors in the +MG group was observed
between day 8 and 12 (Fig. 1), but growth was very
compatible at later time points. Figure 2 illustrate 18F-FDG
PET/CT images of mice from the different groups, and the
compatible 18F-FDG uptake can be readily appreciated at
both time points. The observed compatibility of FDG
uptake in tumors +/− MG indicates that 18F-FDG PET/
CT results are not influenced by the addition of MG
for this tumor model (Fig. 3). SUVmax is often used
clinically for classification of tumors in relation to staging,
treatment, and response, and was therefore included in
study to identify and evaluate maximum uptake in tumors
[20]. No difference between SUVmax in tumors with or
without MG was found, indicating that MG, in this setup,
does not influence maximum FDG uptake (Fig. 3d).
Previous studies have shown that tumor take in models
are increased using MG [21]. In this study the take rate of
tumors inoculated without MG was approximately 95 %
(32 out of 34 inoculated) and 100 % (34 out of 34 inocu-
lated) with MG, which indicates that MG does not influ-
ence tumor take for the investigated model.
The doubling in injection volume between groups might
lead to a falsely determined tumor volume for the +MG
group at early and intermediate time points, where a dis-
tinct part is mostly due to MG volume and not division of
tumor cells. However, as seen in Fig. 1, tumor volume at
Fig. 4 Pearson correlation model for 18F-FDG PET/CT determined tumor volume and external caliper determined tumor volume. Correlation
between external caliper determined volumes and volumes determined from PET/CT scans. Pearson correlation model was used for the plotted
values. a All scans. Correlation coefficient was 0.85 (p-value < 0.0001). b Same regression model with mean value at each time point (5, 8, 12, 15,
and 19). Correlation coefficient was 0.98 (p-value = 0.0017). c Bland-Altman plot showing the difference between measurements against the average
to visualize bias between methods
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day 5 and 8 are virtually similar and the growth rates be-
tween these days follow the same development curve. Dif-
ference in growth rate was detected between day 8 and 12
(increase in rate for +MG). Grounds for injecting larger
suspension volumes for the MG suspension was based on
keeping the injected number of cells and concentration in
media fixed, and from the results the difference in injec-
tion volume did not seem to have a distinct effect. Based
on Figs. 1 and 3, it seems that the variation in size and
tracer uptake is smaller in the −MG group compared to
the +MG group. PET/CT scan data indicate that no sig-
nificant advantage or drawback can be stated regarding
MG use for tumor growth or tumor uptake in this model,
but a decrease in group variation is observed for the −MG
group. Based on this, there is little reason for using MG in
FaDu xenograft models.
Tumor development from IHC data
IHC staining was made on tumors collected at different
size groups in order to compare tumor microenvironment
characteristics on different development stages. Size of
collected tumors was defined using external caliper as
described in the method section. To connect the two parts
of the study in regard to tumor growth, Pearson correl-
ation was performed between volumes determined from
18F-FDG PET/CT scan and volumes determined from the
external caliper (Fig. 4). A correlation coefficient of 0.85
(p-value < 0.0001) was found for the correlation including
all data points (Fig. 4a). Pearson correlation analysis based
on mean values at each time point identified a correlation
coefficient of 0.98 (p-value = 0.0017) (Fig. 4b). Add-
itionally, the validity of comaring tumor sizes between
groups was found acceptable using Bland-Altman analysis
(Fig. 4c).
Results obtained from IHC are presented in Fig. 5.
One-way ANOVA test was used for the comparisons
of characteristics between different size groups. IHC
data showed that vascularization differed between the
groups of the same tumor size. Statistical differences
between micro vessel densities were found for tumor
sizes; 500–700 mm3 (p-value = 0.0457) and 800–1100 mm3
(p-value = 0.0214), and for average vessel area at 500–
700 mm3 (p-value = 0.0237) with the highest numbers for
the -MG group (Fig. 5a and b). Angiogenesis was found to
Fig. 5 Boxplot presentation of immunohistochemical results of collected tumors at different size stages. Results presented from all IHC data
obtained. One way ANOVA with Holm-Sidak’s post hoc test. a MVD as determined by CD31 staining. Significance found between groups of sizes
500–700 mm3 (p-value = 0.0457) and 800–1100 mm3 (p-value = 0.0214). MVD calculated as no. of vessels per ROI area. b Average vessel area incl.
lumen from CD31 staining. Significant difference between groups in tumors size of 500–700 mm3 (p-value = 0.024). c Non-viable cell count presented
from HE staining of slides. No significance found. d Cell density calculated from Haematoxylin staining illustrated, no significant difference found. e Cell
proliferation determined as percent Ki-67 positive cells of total count. No statistical difference observed. f Percentages of hypoxia in tumor from PIMO
antibody staining. No statistical difference found
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be significantly higher in tumors without MG. When
comparing to the results of cell density, a tendency to
a lower median in cell density for tumors without MG
was observed. As discussed previously, tumor growth
data obtained from PET/CT scans showed a tendency
of increased tumor size for the +MG group at day 12–15
where tumors size was 200–400 mm3. Tumor cell prolifer-
ation showed a distinct difference for the small tumor size
group (200–400 mm3) with a higher percentage of pro-
liferating cells in the −MG group (Fig. 5e). These two
observations are conflicting since the increased growth
rate of the tumors in the +MG groups does not correlate
with the proliferation percentage in collected tumors at
same size. The tumor volume in the +MG group could, ac-
cording to the proliferation percentages, hereby partly con-
sist of MG volume but IHC results on other parameters
contradicts this theory. Cell density in tumors of all sizes
seemed to be rather similar, but as described previously, a
lower median is observed for tumors in the −MG group.
This hereby conversely describes the tumor area in +MG to
be denser in cell concentration than the −MG group. For
the larger sized tumor groups proliferating cells in slides
were compatible. In Fig. 6 examples of pre- and post-
analysis images of IHC slides stained with CD31
(Fig. 6a + b), Ki-67 (Fig. 6c + d), and HE (Fig. 6e + f )
are shown. From the IHC results MG seems to be
without major influence on tumor development and
the preclinical outcome in our model.
Conclusions
Our data indicate that using MG in cell suspension for
inoculation induces no major impact on imaging and
microenvironment characteristics of the FaDu hypophar-
yngeal carcinoma xenografts. Less variation is seen when
no MG is used, which is in favor of not including MG in
FaDu xenograft inoculation. Following the extensive use
of the FaDu head and neck cancer xenograft model for
PET imaging and tumor microenvironment characteris-
tics, this study indicates that studies with and without
MG use are comparable. Importantly, the observation in
this study cannot be generally applied. Important differ-
ences potentially exist for human xenograft models other
than FaDu in NMRI nude mice, which must be consid-
ered before comparing results between studies.
Fig. 6 Immunohistochemistry (IHC) sections of micro vessel density (CD31 staining), proliferating cells (Ki-67 staining), and non-viable cell count
(HE staining). Selection of IHC results presented to illustrate collected tissue samples and analyzed tissue. a CD31 staining visualizing endothelial
cells in vessels of tumor slide. Staining made with antibody concentration of 1:50. Picture originates from mouse in the −MG group. Arrows indicate
positive staining of vessels in slide. b Edited version of picture A after using the CAIMAN segmentation algorithm to detect antibody stained
areas. Arrows indicate vessels identified by the CAIMAN algorithm (marked by thin green contouring line). c Ki-67 staining for proliferating
cells in tumor section from a mouse in the +MG group. Staining made using antibody concentration of 1:400. d Review of image C after using
the ImmunoRatio application for selecting proliferating cell percentage. Cells marked in brown are considered as positive Ki-67 and blue cells
negative. e Haematoxylin eosin staining for non-viable cell count in tumor slide from mouse in the +MG group. f Image E after separation of
viable cells (red), non-viable cells (green), and background (purple) with the Advanced Weka Segmentation tool in FiJi (ImageJ)
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